Yamada, Shizuo
University of Shizuoka,
Japan
2025 Rank: 352631
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Urology & Nephrology
Rank in SubField 1: 2984 out of 157499 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 352631 | 346517 |
| Total Cites | 443 | 503 |
| H-index | 7 | 7 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 2 | 2 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 97 | 97 |
| Total Cites to Single+First Authored Papers | 57 | 80 |
| Number of Single+First+Last Authored Papers | 244 | 244 |
| Total Cites to Single+First+Last Authored Papers | 227 | 273 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 365 | 376 |
| Ratio of Total Citations to Distinct Citing Papers | 1.21 | 1.34 |
| Self-Citation Percentage |
11.93%
|
|
Yamada, Shizuo
University of Shizuoka,
Japan
2024 Rank: 338063
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Urology & Nephrology
Rank in SubField 1: 2816 out of 148458 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 338063 | 380323 |
| Total Cites | 440 | 463 |
| H-index | 8 | 8 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 2 | 2 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 93 | 93 |
| Total Cites to Single+First Authored Papers | 38 | 39 |
| Number of Single+First+Last Authored Papers | 238 | 238 |
| Total Cites to Single+First+Last Authored Papers | 194 | 209 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 378 | 388 |
| Ratio of Total Citations to Distinct Citing Papers | 1.16 | 1.19 |
| Self-Citation Percentage |
4.97%
|
|
Yamada, Shizuo
University of Shizuoka,
Japan
2022 Rank: 293120
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Urology & Nephrology
Rank in SubField 1: 2429 out of 134745 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 293120 | 315563 |
| Total Cites | 498 | 558 |
| H-index | 9 | 9 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 2 | 2 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 88 | 88 |
| Total Cites to Single+First Authored Papers | 28 | 32 |
| Number of Single+First+Last Authored Papers | 231 | 231 |
| Total Cites to Single+First+Last Authored Papers | 214 | 247 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 450 | 471 |
| Ratio of Total Citations to Distinct Citing Papers | 1.11 | 1.18 |
| Self-Citation Percentage |
10.75%
|
|
Yamada, Shizuo
University of Shizuoka,
Japan
2021 Rank: 285700
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Urology & Nephrology
Rank in SubField 1: 2329 out of 131063 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 285700 | 292535 |
| Total Cites | 765 | 876 |
| H-index | 11 | 12 |
| Hm-index | 4 | 5 |
| Number of Single Authored Papers | 2 | 2 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 85 | 85 |
| Total Cites to Single+First Authored Papers | 36 | 41 |
| Number of Single+First+Last Authored Papers | 226 | 226 |
| Total Cites to Single+First+Last Authored Papers | 353 | 406 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 664 | 699 |
| Ratio of Total Citations to Distinct Citing Papers | 1.15 | 1.25 |
| Self-Citation Percentage |
12.67%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.